MSD’s Post

To the best of my knowledge, I-Dxd combined with MK-6070 represents the first instance of a combination therapy using an ADC and a bispecific TCE in solid tumors.

Voices of LGSOC Patients, the summary of the first-ever externally led ovarian cancer patient focused drug development meeting is now available. Read it here or on staaroc.org/voices. #lgsoc #lowgradeserousovariancancer #cancerresearch #raredisease

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

Breast, Lung, Colorectal, Prostate. That's one of the things that stands out for me on the infographic here. These are the cancers with the highest incidence but not in kids, which is one of the reasons why so little pediatric oncology research has been done (but this is changing!) #pediatrics #pediatriccancer #raceforchildrenact

⏰ Countdown Alert! Just 2 days until Sheila D. Walcoff, JD, unpacks the FDA's Final Rule for Oncology LDTs at 1 PM ET. Whether you're a seasoned pro or just starting to navigate the complexities of cancer lab regulations, this session is a must-attend. Secure your spot, sharpen your knowledge, and stay ahead of the curve! 🔗 Join the webinar: https://bit.ly/3YFFI3U 🤝 Today's Clinical Lab #LDT #FDA #Oncology #CancerDiagnosis

When a patient is diagnosed with cancer it is often the start of a complex and challenging journey. Evernorth Oncology Benefit Services was designed to meet the needs of patients and plan sponsors through every stage of care in a single experience. Learn how we are transforming oncology care through a holistic, patient-centric, and consultative approach: https://bit.ly/3YfmgJt

Excellent panel here.

Shine a light on hope this May! Bladder, brain, and skin cancers are seeing brighter outlooks thanks to evolving treatments, including #radiopharmaceutical therapies! Let's raise awareness and celebrate progress in the fight against cancer. 💡 Did you know that our website can keep you updated about the latest advancements in #radiotheranostics for cancer care? This is part of our mission to spread the word about this life-changing technology. Check it out: https://buff.ly/3WGVYAs #cancerawareness #radiotheranostic #nuclearmedicine

Fortrea's expert panel will explore the current and future landscape of these CAR-T therapy, highlighting its diverse applications and potential. From revolutionizing treatment approaches in non-oncological diseases to leveraging operational oncology experience for broader therapeutic insights, this webinar will provide valuable lessons and insights into the transformative power CAR-T therapy across various therapeutics.

We are the proud sponsor of the I-SPY 2.2 TRIAL™, the latest evolution in the I-SPY series of trials for early breast cancer. The goal of I-SPY2.2 is very patient centered and straightforward - to find and develop biologically targeted treatments that help get each patient to the best possible outcome with the least toxicity (least side effects). QLHC board member and founder and Co-Principal Investigator of the I-SPY2.2 trial, Dr. Laura Esserman, said about the trial “I have spent much of my career trying to improve the outcomes of women with this early stage (potentially curable) aggressive breast cancer. I-SPY2.2 is the latest in the I-SPY family of trials and introduces a very patient friendly and straightforward trial design. Ultimately, the goal is to find and develop biologically targeted treatments that help get each patient to the best possible outcome, with the least toxicity. I firmly believe this trial is going to do just that.” You can learn more about us and the I-SPY trials, at https://lnkd.in/gWHmVyX9.  . . . #HealthcareForAll #InnovateHealthcare #PersonalizedMedicine #PatientCare #HealthEquity #HealthcareInnovation #BridgingResearchAndCare #IntegrityInHealthcare #CollaborativeCare #TransparencyInHealth #FutureOfHealthcare #ScienceAndCare #HealthcareLeadership #HealthForAll #MedicalInnovation #nonprofit #clinicaltrials #datacollection #healthdata #researchdata #diseaseresearch #findacure #nonprofit